Timber Pharmaceuticals Inc Ordinary Shares TMBR Stock Quote
Morningstar‘s Stock Analysis TMBR
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile TMBR
Timber Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. It is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and scleroderma. The company's development pipeline includes TMB-001 (Topical Isotretinoin), TMB-002 (Topical Rapamycin), and TMB-003 (Topical / Subcutaneous ET-A Receptor Antagonist).